Publications dans lesquelles il/elle collabore avec EVA MARÍA CIRUELOS GIL (8)

2024

  1. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

    Clinical and Translational Oncology

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

2020

  1. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer

    Future Oncology, Vol. 16, Núm. 33, pp. 2763-2778

2019

  1. SEOM clinical guidelines in early stage breast cancer (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 18-30

2015

  1. SEOM clinical guidelines in early-stage breast cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 939-945

2014

  1. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer

    Journal of Cancer Research and Therapeutics, Vol. 10, Núm. 4, pp. 967-972